Programme 2020

Programme

Friday: September 11, 2020

18.30 - 20.00

Welcome Reception

Saturday: September 12, 2020

07.30 - 08.00

Breakfast

08.00 - 08:30

Meeting Registration

08.30 - 08.45

Introduction & Meeting Objectives
John Gribben & Anas Younes

08.45 - 10.15

Session I: T-cell Lymphomas

Chair: Laurence de Leval

  • EBV-associated lymphoproliferations:
    • Pathobiology and Spectrum; Elaine Jaffe
    • Clinical Perspective; Arnaud Jaccard
  • Biology clinics and management of breast implant associated ALCLs:
    • Experience from the French registry; Corinne Haioun
  • Update and perspectives for epigenetic modifier therapy in PTCLs; Owen O’Connor


Roundtable Discussion

10.15 - 10.45

Coffee Break

10.45 - 12.15

Session II: Hodgkin’s Lymphoma

Chair: Anas Younes

  • Early stage; Peter Johnson
  • Advanced stage; Andreas Engert
  • Relapse disease; Alex Herrera
  • Future directions; Anas Younes


Roundtable Discussion

12.15 - 13.15

Lunch

13.15 - 14.45

Session III: Keynote Address – Mantle Cell Lymphoma

Chair & Introduction: Elaine Jaffe

Keynote Speaker: Elias Campo


Roundtable Discussion

14.45 - 15.00

Coffee Break

15.00 - 16.30

Session IV: Immunotherapy / Microenvironment

Chair: David Maloney

  • Targeting the Immune Microenvironment; Massimo Di Nicola
  • CBT in specific lymphoma subtypes; Stephan Ansell
  • Biomarkers that predict for sensitivity to CBT; TBC
  • IMiDs in combination; TBC
  • Checkpoint inhibitors; TBC

19.00

18th iwNHL Dinner

Sunday: September 13, 2020

08.00 - 08.30

Breakfast

08.30 - 10.45

Session V: Novel Therapies

Chairs: Laurie Sehn & Franck Morschhauser

  • ADCs:
    • Polatuzumab vedotin; Laurie Sehn
    • Loncastuximab tesirine; Brad Kahl
    • ADCT-301 camidanlumab tesirine; Graham Collins
  • CD20 / CD3 bispecific antibodies: How to choose?
    • Mosunetuzumab; Stephen Schuster
    • CD20 TCB; Franck Morschhauser
    • REGN1979; Rajat Bannerji
    • DuoBody-CD3xCD20 (GEN3013); Tuna Mutis
  • Oral PI3K delta inhibitors in lymphoma; Owen O’Connor


e-break

  • Novel BTK inhibitors: how to choose?
    • Zanubrutinib; Michael Wang
    • Acalabrutinib; Tom Witzig
    • Loxo0305; Anthony Mato
    • Tirabrutinib; Kensei Tobinai
  • SINE inhibitors: Selinexor; Sundar Jagannath
  • Tafasitamab (MOR208) in DLBCL; Gilles Salles


Roundtable Discussion

10.45 - 11.00

Coffee Break

11.00 - 12.45

Session VI: Clinical Trial Design

Chairs: Andy Zelenetz & Stephen Ansell


Roundtable Discussion

12.45 - 13.30

Lunch

13.30 - 15.30

Session VII: T-cell Therapies for Lymphoma

Chairs: Cath Bollard & Jeremy Abramson 

  • CD19-CAR-T cells:
    • Lisocabtagene maraleucel (liso-cel) in DLBCL; Jeremy Abramson
    • Axicabtagene ciloleucel (axi-cel) in DLBCL; Sattva Neelapu
  • Antigen-specific T-cell overview; Cath Bollard
  • CD30-CAR-T cells; Barbara Savoldo
  • CD5 and/or 7 CAR-T cell; Max Mamonkin
  • Third party EBV T-cells; Susan Prockop


Roundtable Discussion

15.30

Final Meeting Summary & Conclusions
iwNHL Committee

map pin

Location

Meliá Barcelona Sky,
Carrer de Pere IV, 272,
08005 Barcelona, Spain

© 2014 - 2020 World Health Communications Ltd

Media Partner:

Meeting Organizers: